An observational study in Stroke, Ischemic, Genetic Disease and Atherosclerosis, Cerebral, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Chinese University of Hong Kong · Observational
Among 13 studies in Ischemic Stroke by Chinese University of Hong Kong — 7 open to participants now, 7 under way, none of them phase 3. Ischemic Stroke · Chinese University of Hong Kong.
Among the 13 studies in Ischemic Stroke by Chinese University of Hong Kong, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2015, is one of 10 observational ones, and was the 1st registered.
2,617 studies on the registry are indexed under Ischemic Stroke; 976 are open to participants now.
Browse Ischemic Stroke studies →7 of the 13 studies in Ischemic Stroke by Chinese University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 65–80
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–100
Chinese University of Hong Kong · Sites in China, Hong Kong
Ages 18+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Healthy volunteers
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–80
By country, each count listing its studies:
Of the 661 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 300 across 772 observational studies indexed under Ischemic Stroke.
Median enrollment 140 across the 3 interventional studies, 224 across the 10 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Ischemic Stroke by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03291652Chinese University of Hong KongMorphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential | 2026-12-23 |
| NCT03295773Chinese University of Hong KongMorphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography | 2026-12-28 |
| NCT03291392Chinese University of Hong KongCUHK Stroke Biobank | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Ischemic Stroke by Chinese University of Hong Kong, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study are:
TYPES OF TISSUES TO BE BANKED
Blood:
Blood will be collected from the out-patient clinic, prospectively at the time of a clinically planned procedure or prospectively during a procedure performed solely for research. After informed consent is obtained, the patient/ subject will be asked to donate a one-time blood sample of up to 30ml. A portion of each blood sample will be used to generate a DNA sample, and the remainder will be used to separate out plasma, peripheral blood cells, and/or serum for future research studies, including but not limited to metabolomics, proteomics, biomarker measurements, and bioenergetic assays.
Cerebrospinal Fluid:
Cerebrospinal fluid 5-10ml may be collected prospectively from lumbar puncture or the subset of patients who have an external ventricular drain (EVD) placed as part of their clinical care. The standard clinical protocol for EVD includes the drainage of CSF externally into a collection bag. Once the volume of CSF drainage is recorded, the CSF is typically discarded. The collection of CSF will be coordinated with the subject's primary treatment team. At this time, CSF banking will not occur in subjects who do not have CSF collection planned as part of their clinical care.
Body Tissue:
The body tissue will be collected from the patients who undergo the carotid stent which is their routine medical treatment. Around 5mg tissue will be taken from the filter wire during the stenting operation and then stabilized by RNAlater reagent immediately. The tissue will be kept in -80oC freezer for future process.
Buccal swab or saliva:
Buccal swab or saliva (\~5-10ml) may be collected from the patients, their family members and/or normal subjects for DNA and RNA extraction if necessary. It would be collected by the trained doctor, medical staffs or research assistant. The collected samples will be kept in -80oC freezer for future use, for example, extraction of DNA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases
Genetic: Gene expression or biomarkers exploration
The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases
Genetic: Gene expression or biomarkers exploration
Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking. Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases
Genetic: Gene expression or biomarkers exploration
Ischemic stroke-related genetics
1. Discovery of novel genetic predictor of stroke and its complications will be done by identifying cases and controls for different stroke subtype and complications within the recruited samples, and using whole-genome genotyping arrays, or by sequencing approaches. 2. Replication of novel genetic markers of stroke will be performed using a combination of genotyping, multiplex genotyping, customized-content genotyping arrays and sequencing.
Time frame: Dec, 2025
Plan to share: Undecided — Tissues and data from the repository will only be shared with other academic, non-profit institutions. No collaboration with for-profit companies is anticipated. All investigators seeking to gain access to the repository must first demonstrate that their research interests are relevant to the central theme of the repository. Investigators must also complete all required IRB documentation before samples and information will be released. In the event that a commercial, for-profit, collaboration is sought, a bona fide intellectual collaboration between the PI and an individual or group at the for-profit site and a Materials Transfer Agreement will be required. For all researchers requesting samples, the IRB recommended Letter of Agreement must be signed prior to our releasing tissues and information.
No publications or documents are linked to this record.
Started Jun 2015 (actual). Primary completion is estimated for Dec 2026, 138 months after the start.
Of 396 non-industry observational studies under Ischemic Stroke, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 138 months is above that.
Counting every sponsor, half of 438 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →